RA CAPITAL MANAGEMENT, L.P. purchased $2.6M of ARTV (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 264,586 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.76 ($9.55–$9.96, $2.58M total) across 3 trades over 2026-07-21 to 2026-07-23.
How this was made
The 30-second read
Why it matters
Traders may use the disclosed accumulation as a sentiment input, but there is no accompanying operational update (earnings, trial results, approvals, or guidance).
Market read
A $2.58M open-market purchase by a large insider-holder is newly disclosed, offering a modest sentiment signal for ARTV.
What to watch
No 10b5-1 plan is stated, but the filing does not clarify intent, tax considerations, or whether the purchases were pre-planned through other vehicles.
Background
The article is an SEC Form 4 insider transaction disclosure for Artiva Biotherapeutics, Inc. (ARTV).
Ticker impact
RA Capital Management, a director and 10% owner, bought 264,586 shares of Artiva Biotherapeutics in open-market trades totaling about $2.58M.
Likely limited near-term impact; could modestly support sentiment if traders treat it as a signal, but it is not a fundamental catalyst.
Form 4 provides a fresh, time-stamped transaction (2026-07-21 to 2026-07-23) with a meaningful dollar value, yet the filing does not include new company fundamentals or guidance.
Market effects
Minimal; single-company biotech insider purchase without clinical or regulatory updates.
None indicated.
None indicated.
Counterpoint
Indirect holdings and multi-trade execution can reflect portfolio rebalancing rather than a new view on near-term fundamentals.
Key entities
- issuerArtiva Biotherapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- reporterRA Capital Management, L.P.
Director and 10% owner who reported an open-market purchase via indirect holdings.
